WBB Securities upgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday morning, Marketbeat.com reports.

“Mesoblast announced continued positive survival data for remestemcel-L (allogeneic cell therapy) in children with steroid refractory acute graft vs. host disease (aGvHD). The next step for the company is meeting with FDA to discuss BLA submission. The cell therapy is already approved in Japan (as TEMCELL HS Inj) for aGvHD, licensed to JCR Pharmaceuticals Co Ltd (TYO: 4552 – NR).”,” the firm’s analyst wrote.

ARCT has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Arcturus Therapeutics from a hold rating to a sell rating in a research report on Monday, June 18th. ValuEngine upgraded Arcturus Therapeutics from a sell rating to a hold rating in a report on Wednesday, June 6th. Finally, LADENBURG THALM/SH SH upgraded Arcturus Therapeutics from a neutral rating to a buy rating in a report on Thursday, May 31st. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $4.06.

NASDAQ:ARCT opened at $9.80 on Thursday. The company has a market cap of $105.29 million, a price-to-earnings ratio of -2.78 and a beta of 1.44. Arcturus Therapeutics has a fifty-two week low of $4.78 and a fifty-two week high of $15.19.

A hedge fund recently raised its stake in Arcturus Therapeutics stock. ARK Investment Management LLC grew its holdings in shares of Arcturus Therapeutics Ltd (NASDAQ:ARCT) by 61.2% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 533,773 shares of the biotechnology company’s stock after buying an additional 202,608 shares during the period. ARK Investment Management LLC owned approximately 4.97% of Arcturus Therapeutics worth $4,526,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 7.65% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Further Reading: Hedge Funds

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.